Replies to post #158088 on Biotech Values

[poorgradstudent]

ONXX:

The National Comprehensive Cancer Network (NCCN) adds the combination of carfilzomib, which is sold by Onyx Pharmaceuticals (ONXX), lendalidomide and dexamethasone to its guidelines as an option for treating multiple myeloma patients who are also transplant candidates. The NCCN also adds carfilzomib monotherapy and other agents as a preferred treatment regimen for salvage therapy. The FDA hasn't approved carfilzomib for these uses, so Onyx won't market carfilzomib for them

I think this is pretty big news for ONXX. Just goes to show you that stocks with 2-3 billion dollar market caps can also double.